Literature DB >> 28271528

The animal naming test: An easy tool for the assessment of hepatic encephalopathy.

Francesca Campagna1, Sara Montagnese1, Lorenzo Ridola2, Marco Senzolo3, Sami Schiff1, Michele De Rui1, Chiara Pasquale2, Silvia Nardelli2, Ilaria Pentassuglio2, Carlo Merkel1, Paolo Angeli1, Oliviero Riggio2, Piero Amodio1.   

Abstract

Screening for hepatic encephalopathy (HE) that does not cause obvious disorientation or asterixis (minimal HE [MHE]/grade 1 HE) is important. We examined if the animal naming test (ANT1 ) (maximum number of animals listed in 1 minute) is useful in this context. In total, 208 healthy controls, 40 controls with inflammatory bowel disease, and 327 consecutive patients with cirrhosis underwent the ANT1 . Patients were tested for MHE by the psychometric HE score, and 146 were assessed by electroencephalography; 202 patients were followed up regarding the occurrence of overt HE and death. In the healthy controls, ANT1 was influenced by limited education (<8 years) and advanced age (>80 years, P < 0.001). Using an age and education adjusting procedure, the simplified ANT1 (S-ANT1 ) was obtained. An S-ANT1 of <10 animals was abnormal. Of the patients, 169 were considered unimpaired, 32 as having HE ≥grade 2, and 126 as having MHE/grade 1 HE. This group had lower S-ANT1 than unimpaired patients (12 ± 0.4 versus 16 ± 0.7, P < 0.001) and higher S-ANT1 than those with HE ≥grade 2 (4 ± 0.9). In grade 1 HE the S-ANT1 was lower than in MHE. Following receiver operating characteristic analysis (Youden's index), 15 animals produced the best discrimination between unimpaired and MHE/grade 1 HE patients. Thus, a three-level score (0 for S-ANT1 ≥15, 1 for 10 ≤ S-ANT1 < 15, 2 for S-ANT1 <10) was obtained. This score was correlated both to the psychometric HE score (P < 0.0001) and to electroencephalography (P = 0.007). By sample random split validation, both S-ANT1 and its three-level score showed prognostic value regarding the 1-year risk of overt HE and death. No inflammatory bowel disease control had S-ANT <15.
CONCLUSION: The S-ANT1 is an easily obtainable measure useful for the assessment of HE. (Hepatology 2017;66:198-208).
© 2017 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2017        PMID: 28271528     DOI: 10.1002/hep.29146

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  31 in total

1.  Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests.

Authors:  Elliot B Tapper; Neehar D Parikh; Akbar K Waljee; Michael Volk; Noelle E Carlozzi; Anna S-F Lok
Journal:  Am J Gastroenterol       Date:  2018-03-13       Impact factor: 10.864

Review 2.  Transjugular intrahepatic portosystemic shunt (TIPS): current indications and strategies to improve the outcomes.

Authors:  Francesco Vizzutti; Filippo Schepis; Umberto Arena; Fabrizio Fanelli; Stefano Gitto; Silvia Aspite; Laura Turco; Gabriele Dragoni; Giacomo Laffi; Fabio Marra
Journal:  Intern Emerg Med       Date:  2020-01-09       Impact factor: 3.397

3.  Cognitive Function, Sarcopenia, and Inflammation Are Strongly Associated with Frailty: A Framingham Cohort Study.

Authors:  Manaav Mehta; Jeremy Louissaint; Neal S Parikh; Michelle T Long; Elliot B Tapper
Journal:  Am J Med       Date:  2021-08-28       Impact factor: 4.965

Review 4.  Hepatic encephalopathy.

Authors:  Dieter Häussinger; Radha K Dhiman; Vicente Felipo; Boris Görg; Rajiv Jalan; Gerald Kircheis; Manuela Merli; Sara Montagnese; Manuel Romero-Gomez; Alfons Schnitzler; Simon D Taylor-Robinson; Hendrik Vilstrup
Journal:  Nat Rev Dis Primers       Date:  2022-06-23       Impact factor: 65.038

Review 5.  Specific Challenges in Geriatric Cirrhosis and Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Angela Gentili; James B Wade; Michael Godschalk
Journal:  Clin Gastroenterol Hepatol       Date:  2022-08       Impact factor: 13.576

6.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

7.  Factors That Affect Results of Psychometric Tests to Identify Patients With Minimal Hepatic Encephalopathy.

Authors:  Maria Camila Pérez-Matos; Z Gordon Jiang; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-15       Impact factor: 11.382

8.  Assessment of the spectrum of hepatic encephalopathy: A multicenter study.

Authors:  Bradley Reuter; Kara Walter; Julien Bissonnette; Michael D Leise; Jennifer Lai; Puneeta Tandon; Patrick S Kamath; Scott W Biggins; Christopher F Rose; James B Wade; Jasmohan S Bajaj
Journal:  Liver Transpl       Date:  2018-05       Impact factor: 5.799

9.  Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery.

Authors:  Burak Özbaş; Onur Keskin; Hartmut Hecker; Irfan Karahan; Cansu Özbaş; Çağdaş Kalkan; Aysun Kartal; Fatih Oğuz Önder; Burcu Kahveci Öncü; Genco Gençdal; Murat Akyildiz; Fulya Günşar; Ramazan Idilman; Karin Weissenborn; Ömer Özütemiz; Cihan Yurdaydin
Journal:  Hepatol Int       Date:  2021-06-03       Impact factor: 6.047

10.  The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis.

Authors:  Nina Kimer; Lise Lotte Gluud; Julie Steen Pedersen; Juliette Tavenier; Søren Møller; Flemming Bendtsen
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.